Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

which enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance. Eli Lilly and Company (NYSE: LLY) will ...

Late-breaking results from Eli Lilly and Company (LLY) and Incyte (INCY) found adolescent patients with severe alopecia areata, AA, treated with once-daily, oral baricitinib 4 mg and 2 mg saw ...

The firm sees limited impact to Eli Lilly shares and says the focus remains on weekly scripts and Orfor Phase 3 data due in Q2. Morgan Stanley has an Overweight rating and $1,146 price target on ...

Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.

5:16 PM UTC Eli Lilly plans to launch weight-loss drug in emerging markets this year Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...